This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CDK9 / Cyclin-dependent kinase 9 · IHC design guide
Design Immunohistochemistry for CDK9
CDK9 shows ubiquitous nuclear staining in tissue (HPA tissue IHC). This guide helps plan paraffin-section IHC and interpret staining in light of reported cytoplasmic localisation and replication stress–associated chromatin accumulation (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
CDK9 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear in tissue; a cytoplasmic pool is reported (HPA tissue IHC; UniProt) | |
| Staining pattern | Widespread nuclear staining across cell types (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet M00794) | |
| Positive control | Adipose tissue+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Replication stress may alter the nuclear staining pattern (UniProt) | |
| Regulation | Replication stress: chromatin accumulation (UniProt) | |
| Isoform / epitope | Two isoforms; epitope coverage needs verification (UniProt) |
Section 1
Recommended CDK9 IHC & IF Protocols
The catalog antibody’s IHC-P workflow is accompanied by four published CDK9 IHC protocols (datasheet M00794; PMC10045754; PMC8136118; PMC7551504; PMC6865572).
| Sample | Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet M00794) |
| Fixation | Image fixative and duration unreported (datasheet M00794); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet M00794); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet M00794) |
| Primary antibody | Rabbit monoclonal (clone GIH-3) anti-CDK9, 1:50 (datasheet M00794) |
| Primary incubation | Overnight at 4 °C (datasheet M00794) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet M00794) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | CDK9-positive staining in adipocytes of adipose tissue (HPA tissue IHC: High). HPA tissue profile: Ubiquitous nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 heat retrieval for the catalog antibody (datasheet M00794). Use each article’s retrieval conditions when reproducing its assay (PMC10045754; PMC8136118; PMC7551504; PMC6865572).
Section 2
What Is the Expected CDK9 Staining Pattern?
Expect CDK9 staining mainly in nuclei across many cell types: HPA describes ubiquitous nuclear expression and reports high staining in the listed positive cells (HPA: tissue IHC, Supported). Nuclear localisation is consistent with CDK9’s transcriptional role; UniProt also places CDK9 in the cytoplasm and reports no transmembrane segment (UniProt P50750: function, localisation, topology).
| Many nuclei stain in an HPA-listed tissue, including adipocytes, adrenal glandular cells, or bone-marrow hematopoietic cells. | This fits the reported ubiquitous nuclear pattern and High staining in those cells (HPA: tissue IHC, Supported). Judge the signal in identifiable cells, alongside the counterstain and controls; HPA’s levels do not set an intensity cutoff for every laboratory (general IHC practice). |
| A section shows predominantly diffuse cytoplasmic, membranous, or extracellular colour, with little nuclear staining. | That distribution conflicts with the supported IHC tissue profile (HPA: ubiquitous nuclear expression). UniProt allows some cytoplasmic CDK9, so a cytoplasmic component alone is not proof of artefact (UniProt P50750: localisation). Check whether the unexpected colour persists in a no-primary control (general IHC practice). |
| Strong colour is confined to an unexpected cell population while nearby identifiable nuclei lack signal. | Consider cross-reactivity or endogenous detection activity, especially if control staining follows the same cells (general IHC practice). Do not label a population CDK9-negative solely because it is absent from HPA’s short positive list: HPA describes ubiquitous nuclear expression (HPA: tissue IHC). |
| Colour spreads through stroma or across the section and obscures nuclear boundaries. | Treat that as background until controls clarify it; diffuse colour cannot establish nuclear CDK9 localisation (general IHC practice; HPA: ubiquitous nuclear expression). Review blocking, washes, detection reagents, and the no-primary control (general IHC practice). |
| A listed positive cell population has no convincing nuclear signal. | An absent signal in, for example, adrenal glandular cells or bone-marrow hematopoietic cells conflicts with their reported High staining (HPA: tissue IHC). Check section quality, detection, antibody use, and a same-run positive control before interpreting biological absence (general IHC practice). |
💡Expected CDK9 appearanceCall the result positive when identifiable cells show clear nuclear chromogen, including strong staining in HPA-listed High populations; diffuse extracellular colour alone is a false-positive pattern (HPA: tissue IHC; general IHC practice).
| Compartment | Use nuclei as the principal IHC readout (HPA: ubiquitous nuclear expression, Supported). Cytoplasmic CDK9 is biologically possible, but HPA’s tissue profile does not establish cytoplasm as the dominant paraffin-section pattern (UniProt P50750: localisation; HPA: tissue IHC). |
| Tissue and cell context | HPA reports High staining in adipocytes, respiratory epithelial cells, caudate glial cells, and cerebellar granular-layer cells, among others (HPA: tissue IHC). Its positive list is selective; the overall profile is ubiquitous nuclear expression (HPA: tissue IHC). |
| Antibody evidence | HPA rates IHC staining Supported for HPA006738 and CAB004216 (HPA: antibody validation). Supported is the stated status; this payload does not establish Enhanced validation or guarantee the pattern for another antibody (HPA: antibody validation). |
| Isoforms and modifications | UniProt lists two isoforms and multiple modified residues (UniProt P50750: isoforms, modified residues). No supplied epitope map or IHC comparison shows that either feature changes staining with a given antibody; avoid assigning unexplained signal differences to them. |
| Paraffin-section workflow | Optimise antigen retrieval and antibody dilution according to the selected IHC-validated antibody’s instructions, using a positive control (general IHC practice). The supplied HPA and UniProt data provide no CDK9-specific retrieval condition, dilution, or fixation-sensitivity claim. |
| IF/ICC cross-check | What pattern might IF/ICC show? HPA places CDK9 mainly in the nucleoplasm (approved), with cytoplasmic bodies marked uncertain (HPA: subcellular ICC-IF). That observation can inform localisation review; it is not an IHC-P protocol or proof of a cytoplasmic tissue pattern. |
| Situation | Likely cause | Next action |
|---|---|---|
| No nuclear colour in a listed High population. | The run may have failed, or the selected antibody conditions may be unsuitable (general IHC practice); HPA reports High staining in the listed cells (HPA: tissue IHC). | Inspect a same-run positive section and detection controls, then review the selected antibody’s IHC-P instructions and retrieval settings (general IHC practice). |
| Only faint nuclei are visible, with a working positive control. | Signal may be below the run’s practical detection threshold (general IHC practice). HPA levels describe its observations, not a required intensity in this assay (HPA: tissue IHC). | Review antibody dilution and detection conditions within the selected antibody’s instructions; compare cells and sections processed in the same run (general IHC practice). |
| Colour remains when primary antibody is omitted. | The signal arises from the detection workflow rather than primary-antibody binding; endogenous activity or nonspecific reagent binding may contribute (general IHC practice). | Check the detection chemistry and relevant blocking steps, then repeat the no-primary control before scoring CDK9 (general IHC practice). |
| Predominant cytoplasmic colour is reproducible, but nuclei are weak. | UniProt reports a cytoplasmic pool, yet this distribution differs from HPA’s ubiquitous nuclear tissue pattern (UniProt P50750: localisation; HPA: tissue IHC). | Compare nuclear and cytoplasmic staining in a listed positive tissue, inspect controls, and verify that the antibody is IHC-validated (HPA: tissue IHC and antibody validation; general IHC practice). |
| An unexpected cell group stains much more strongly than surrounding cells. | The pattern could reflect an assay effect or real variation; HPA’s ubiquitous nuclear profile does not define every cell’s relative intensity (HPA: tissue IHC). | Identify the cells by morphology, compare a no-primary control, and seek concordant nuclear staining with an independently validated antibody if available (general IHC practice). |
| Background makes nuclei hard to distinguish. | Nonspecific chromogen deposition or detection background can prevent compartment assessment (general IHC practice). | Review washes, blocking, and detection conditions; use the counterstain to locate nuclei and score only interpretable cells (general IHC practice). |
Experiment evidence
IHC & IF images showing CDK9 staining
M00794 · IHCIHC analysis of CDK9 using anti-CDK9 antibody (M00794). CDK9 was detected in a paraffin-embedded section of human breast cancer tissue. Heat
M00794 · IHCIHC analysis of CDK9 using anti-CDK9 antibody (M00794). CDK9 was detected in a paraffin-embedded section of human prostate cancer tissue. He
PB9537 · IHCIHC analysis of Cdk9 using anti-Cdk9 antibody (PB9537). Cdk9 was detected in a paraffin-embedded section of rat intestine tissue. Heat media
PB9537 · IHCIHC analysis of Cdk9 using anti-Cdk9 antibody (PB9537). Cdk9 was detected in a paraffin-embedded section of human intestinal cancer tissue.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000136807-CDK9/tissue/cerebral+cortex#imid_2106784
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000136807-CDK9/tissue/colon#imid_2106694
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000136807-CDK9/tissue/liver#imid_2106711
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000136807-CDK9/tissue/kidney#imid_2106704
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA006738; green = CDK9, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA006738; green = CDK9, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for CDK9 IHC & IF
🧪Run breast tissue first: glandular cells should show CDK9 staining, predominantly in nuclei (HPA: High in breast glandular cells; UniProt P50750: nucleus). HPA detects CDK9 in all 45 scored tissues and lists no negative tissue, so use no-primary and isotype slides as negative controls; any unstained cells on the positive slide indicate local background but are not validated CDK9-negative cells (HPA: no negative rows; detected in all 45 tissues).
Positive control tissue: Adipose tissue (Adipocytes, HPA High)
Negative control tissue: None in HPA: CDK9 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show CDK9 in A-431, U-251MG, U2OS, with annotated localisation: Nucleoplasm (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only slide and a control immunoglobulin matched to the rabbit primary’s isotype and clonality; where available, use CDK9 knockout material as a biological specificity control (M00794 caption: rabbit primary; standard IHC practice). For breast sections developed with HRP/DAB, quench endogenous peroxidase and inspect the no-primary slide for tissue background (M00794 caption: HRP/DAB detection; standard IHC practice).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported, and the selected M00794 paraffin-section caption does not state a fixative (M00794 caption: fixative unreported). That example used heat retrieval in EDTA at pH 8.0 before staining at 1:50; it does not establish that retrieval condition as universally required (M00794 caption). Frozen-section performance is unreported; HPA has ICC-IF images showing mainly nucleoplasmic localization, but the supplied evidence does not establish frozen sections or IF as easier for tissue work (HPA subcellular; M00794 caption).
HPA tissue IHC evidence for CDK9
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: CDK9 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced CDK9 IHC Tips
Use the IHC tissue example and CDK9 localisation evidence to troubleshoot nuclear staining in paraffin sections; treat IF/ICC as a separate application.
How should I retrieve CDK9 in paraffin sections with weak nuclear staining?
Start with heat-mediated retrieval in EDTA at pH 8.0 for paraffin sections (datasheet M00794). The selected CDK9 tissue image used this retrieval before 1:50 primary antibody incubation overnight at 4°C (datasheet M00794). If nuclear staining remains weak, compare a longer retrieval exposure with the original condition on adjacent sections, while checking tissue morphology for heat damage (standard IHC practice). Keep the antibody dilution, detection, and DAB development matched during that comparison so the retrieval change can be judged independently (standard IHC practice). Score nuclei first, because ubiquitous nuclear expression is the supported tissue pattern (HPA: Supported; ubiquitous nuclear expression).
Could fixation explain uneven CDK9 staining across my paraffin sections?
Target-specific sensitivity of CDK9 staining to fixation is unknown from the supplied evidence; the selected paraffin-section caption does not state a fixative (datasheet M00794). Do not assign a formalin-specific effect to CDK9 from its tissue pattern or molecular features (HPA: ubiquitous nuclear expression; UniProt P50750: kinase domain 19–315). Record each block’s fixative, fixation interval, section age, and storage conditions before comparing cases (standard IHC practice). Run adjacent sections with the same EDTA pH 8.0 retrieval, 1:50 primary dilution, and DAB development, then assess staining alongside morphology (datasheet M00794; standard IHC practice).
Is cytoplasmic CDK9 staining compatible with a valid nuclear IHC result?
Expect predominantly nuclear staining in tissue, because the supported tissue profile is ubiquitous nuclear expression (HPA: Supported; ubiquitous nuclear expression). CDK9 can also occur in the cytoplasm, and its uncomplexed form is cytoplasmic while the CCNT1-complexed form occupies nuclear speckles (UniProt P50750: subcellular localisation). Its main approved subcellular location is nucleoplasm; cytoplasmic bodies are an additional uncertain location (HPA: subcellular). Compare the nuclear-to-cytoplasmic pattern across intact cells and adjacent sections before treating a cytoplasmic signal as biological (standard IHC practice). Diffuse staining confined to damaged edges or poorly preserved areas warrants review of morphology and controls (standard IHC practice).
Could an unmapped epitope change what my CDK9 IHC stain represents?
The supplied record lists CDK9 isoforms 1 and 2, but the selected antibody caption does not map its epitope (UniProt P50750: isoforms; datasheet M00794). Therefore, do not report isoform-specific staining from this antibody without separate epitope and specificity evidence (standard IHC interpretation). CDK9 has a protein kinase domain at residues 19–315 and documented modifications including acetylation at 44 and 48 and phosphorylation at 186 (UniProt P50750: domains; modified residues). When staining differs by condition, review epitope documentation and matched controls before attributing the change to a specific isoform or modification (standard IHC practice).
How should I assess CDK9 by IF alongside cell-type markers?
Treat IF/ICC as a separate application: the selected antibody evidence describes chromogenic IHC in a paraffin section, with no fixative stated (datasheet M00794). For multiplex IF, pair CDK9 with a validated marker for the expected cell type and a nuclear counterstain, then assess signal within those cells (standard IF practice; HPA: ubiquitous nuclear expression). Choose spectrally separated fluorophores and inspect unstained tissue for autofluorescence before assigning a weak CDK9 signal (standard IF practice). CDK9 has no transmembrane segment, so assess permeabilisation for access to its intracellular, chiefly nucleoplasmic location while preserving cell morphology (UniProt P50750: topology; HPA: nucleoplasm approved; standard IF practice).
What should I check when CDK9 DAB staining looks diffuse or widespread?
Widespread nuclear staining can be plausible because CDK9 shows ubiquitous nuclear expression, so background must be judged by compartment and controls (HPA: Supported; ubiquitous nuclear expression). The selected tissue method used 10% goat serum, 1:50 rabbit primary overnight at 4°C, a peroxidase-linked secondary, and DAB (datasheet M00794). Include a no-primary control and check peroxidase blocking and DAB development when diffuse brown signal obscures nuclei (standard chromogenic IHC practice). If background persists, compare shorter development or adjusted primary concentration on adjacent sections while keeping retrieval fixed at EDTA pH 8.0 (datasheet M00794; standard IHC practice).
How can I quantify CDK9 IHC without counting nonspecific cytoplasmic stain? ⚠ ANSWER MARKED FOR VERIFICATION
Define the scored compartment as nuclei, matching the supported ubiquitous nuclear tissue profile and approved nucleoplasmic location (HPA: tissue IHC; HPA: subcellular). On each section, report the percentage of positive nuclei and, if intensity is reproducibly graded, a nuclear H-score using 0–3 intensity bins (standard IHC scoring practice). Normalise counts to evaluable nuclei within the same annotated cell population, or report positive nuclear density per mm² of viable tissue (standard IHC scoring practice). Keep retrieval, 1:50 primary dilution, and DAB development consistent across the comparison set, and exclude folds, edges, and necrotic areas before scoring (datasheet M00794; standard IHC practice).
How do I distinguish genuine CDK9 signal from IHC artefact?
Give greatest weight to staining in intact nuclei across the expected cell population, consistent with the supported ubiquitous nuclear tissue profile (HPA: Supported; ubiquitous nuclear expression). Cytoplasmic staining is biologically possible, but the approved main location is nucleoplasm and the additional cytoplasmic-body assignment is uncertain (UniProt P50750: subcellular localisation; HPA: subcellular). Review staining restricted to section edges, folds, necrosis, or an unexpected cell population against morphology and adjacent sections (standard IHC practice). A no-primary control and effective peroxidase block help identify detection background or endogenous enzyme activity before interpreting DAB deposits as CDK9 (standard chromogenic IHC practice).
Boster reagents
Best CDK9 / Cyclin-dependent kinase 9 IHC Antibodies
Two anti-CDK9 antibodies have real IHC images from paraffin sections (catalog image captions). M00794 also lists IF/ICC; the catalog provides no IF image (M00794 applications; catalog IF images).
Real IHC data
Anti-CDK9 Rabbit Monoclonal Antibody
Cat # M00794
Real IHC data
Anti-Cdk9 Antibody ®
Cat # PB9537
M00794 will render with a human breast cancer paraffin-section IHC image; its catalog lists human, mouse and rat reactivity and IF/ICC use (M00794 image caption; catalog applications/reactivity). PB9537 will render with a rat intestine paraffin-section IHC image; its catalog lists human and rat reactivity (PB9537 image caption; catalog reactivity).
Which to pick: For tissue IHC, both have paraffin-section images; choose M00794 for its rabbit monoclonal clone GIH-3 or PB9537 for its rat intestine example (catalog clone; M00794 and PB9537 image captions). For IF/ICC, choose M00794 because IF/ICC is listed at 1:50, although no IF image is provided (catalog applications/dilution/IF images). For work spanning human, mouse and rat, choose M00794; its paraffin-section images cover all three species, while PB9537 lists human and rat reactivity (catalog reactivity; IHC image captions). Fixative is unreported for both IHC examples (M00794 and PB9537 image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P50750 (CDK9_HUMAN, Cyclin-dependent kinase 9).
- Human Protein Atlas. CDK9 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. CDK9 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the cytoplasmic bodies..
- Human Protein Atlas. CDK9 antibody validation summary (2 antibodies).
- Evaluation of CDK9 Inhibition by Dinaciclib in Combination with Apoptosis Modulating izTRAIL for the Treatment of Colorectal Cancer. Biomedicines 2023 — PMC10045754.
- Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer. Journal of ovarian research 2021 — PMC8136118.
- Targeting CDK9: A novel biomarker in the treatment of endometrial cancer. Oncology reports 2020 — PMC7551504.
- Cyclin-dependent kinase 9 expression and its association with CD8(+) T cell infiltration in microsatellite-stable colorectal cancer. Oncology letters 2019 — PMC6865572.
- PubMed PMID:8170997 — UniProt-cited evidence.
- PubMed PMID:7695608 — UniProt-cited evidence.
- PubMed PMID:10903437 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for CDK9 (Cyclin-dependent kinase 9). Expected localisation Nuclear in tissue; a cytoplasmic pool is reported (HPA tissue IHC; UniProt). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet M00794). Validated IHC antibody: M00794 at 1:50 (the product's own IHC validation image is shown). Controls (HPA): positive Adipose tissue (Adipocytes); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet M00794); 2. Fixation: Image fixative and duration unreported (datasheet M00794); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet M00794); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet M00794); 8. Primary antibody: Rabbit monoclonal (clone GIH-3) anti-CDK9, 1:50 (datasheet M00794); 9. Primary incubation: Overnight at 4 °C (datasheet M00794). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Replication stress may alter the nuclear staining pattern (UniProt); Isoform / epitope: Two isoforms; epitope coverage needs verification (UniProt); Regulation: Replication stress: chromatin accumulation (UniProt). Evidence: UniProt P50750, HPA tissue IHC · Supported, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet M00794, PMC10045754, PMC8136118. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/CDK9/immunohistochemistry-ihc-guide.